We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Clues to Cause of Stomach Cancer

By Biotechdaily staff writers
Posted on 24 Sep 2002
Researchers have found that mutations on a receptor molecule called gp130 in mice resulted in symptoms that mirrored those of gastric cancer and large bowel inflammation in humans, suggesting targets for drugs to treat these conditions. More...
The research was reported in the October 2002 issue of Nature Medicine.

The gp130 molecule is found on the surface of cells and is traditionally involved in helping to regulate the body's immune system. The molecule serves as a molecular antenna, transmitting instructions from cytokines to individual cells, telling them how to respond to their environment. The researchers were surprised when mice carrying the mutations in gp130 developed cellular changes similar to those of gastric cancer.

"Nobody suspected that interference with the messenger service engaged by gp130 could be linked with a 100% prevalence of early stages of gastric cancer in mice,” said Andy Giraud, associate professor at the University of Melbourne (Australia) and a member of the research team.

On set of mice had a single amino acid change to the gp130 molecule, which induced the changes reminiscent of early gastric cancer. A second set of mice has a small chunk chopped off the end of the molecule. This set showed reduced ability to repair damage in the colon and rectum, making them susceptible to intestinal injury resulting in large bowel inflammation.

"What has been designed as a regenerative mechanism gets out of control in the stomach with one mutation, while not being activated in the large bowel as a result of the other mutation. What we have yet to find is the cancer spreading to other organs, which is what eventually kills patients,” said Dr. Matthias Ernst, of the Ludwig Institute for Cancer Research in Melbourne, also a member of the research team.




Related Links:
University of Melbourne

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.